Microdosing Psilocybin for Depression

This double-blind randomized-controlled trial will assess the effects of two small doses of synthetic psilocybin (5mg) in capsule form each week for six weeks in people with depression.

With 266 participants and funding in the region of $5.6 million AUD, this is one of the largest psychedelic studies to take place in Australia to date.

Topic Depression Microdosing

Compound Psilocybin

Country Australia

Visit trial

Status Planned

Results Published No

Start date 01 November 2022

Chance of happening 79%

Phase Phase II

Design Blinded

Type Interventional

Generation Second

Participants 266

Sex All

Age 18- 99

Therapy No

Trial Details

NCT Number

Sponsors & Collaborators

Woke Pharmaceuticals
Woke Pharmaceuticals is an Australian biotech company developing novel psychedelic compounds.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.